Patents by Inventor Donald Metcalf
Donald Metcalf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080274973Abstract: The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: July 1, 2008Publication date: November 6, 2008Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Publication number: 20080166730Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: ApplicationFiled: October 23, 2007Publication date: July 10, 2008Applicant: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Patent number: 7279557Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: GrantFiled: November 17, 2004Date of Patent: October 9, 2007Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Publication number: 20060242718Abstract: The present invention relates generally to amino acid sequences obtainable from SOCS proteins and which are capable of interacting with intracellular molecules. The present invention further relates to nucleic acid molecules encoding said amino acid sequences. The amino acid sequences and the nucleic acid molecules encoding same of the present invention are useful in modulating degradation of proteinaceous molecules such as but not limited to SOCS proteins and proteinaceous molecules associate therewith. The present invention provides a mechanism for modulating cytokine or cytokine-like molecule signaling by modulating the degradation of activated signal transduction molecules or their negative regulators, i.e. the SOCS proteins.Type: ApplicationFiled: April 10, 2006Publication date: October 26, 2006Inventors: Tracy Willson, Richard Simpson, Alison Farley, Sandra Nicholson, Jian Zhang, Manuel Baca, Nicos Nicola, Douglas Hilton, Warren Alexander, Donald Metcalf
-
Patent number: 7078174Abstract: The present invention relates generally to amino acid sequences obtainable from SOCS proteins and which are capable of interacting with intracellular molecules. The present invention further relates to nucleic acid molecules encoding said amino acid sequences. The amino acid sequences and the nucleic acid molecules encoding same of the present invention are useful in modulating degradation of proteinaceous molecules such as but not limited to SOCS proteins and proteinaceous molecules associated therewith. The present invention provides a mechanism for modulating cytokine or cytokine-like molecule signalling by modulating the degradation of activated signal transduction molecules or their negative regulators, i.e. the SOCS proteins.Type: GrantFiled: December 21, 1999Date of Patent: July 18, 2006Assignee: The Walter & Eliza Hall Institute of Medical ResearchInventors: Tracy Ann Willson, Richard John Simpson, Alison Mary Farley, Sandra Elaine Nicholson, Jian-Guo Zhang, Manuel Baca, Nicos A. Nicola, Douglas J. Hilton, Warren Scott Alexander, Donald Metcalf
-
Patent number: 7049418Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: GrantFiled: July 19, 2001Date of Patent: May 23, 2006Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Publication number: 20060093604Abstract: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of inflammatory conditions such as but not limited to chronic immune-mediated inflammatory diseases. The present invention further provides pharmaceutical compositions comprising agents which inhibit one or more inflammatory cytokines and/or which down-regulate expression of genes which encode inflammatory cytokines. Such compositions are useful in the treatment and prophylaxis of inflammatory conditions such as inflammatory arthritis amongst other chronic immune-mediated inflammatory diseases. The present invention further provides an animal model for studying the kinetics of and/or screening for agents useful in the treatment or prophylaxis of inflammatory conditions.Type: ApplicationFiled: August 22, 2003Publication date: May 4, 2006Applicant: The Walter and Eliza Hall Institute of Medical ResearchInventors: Kathryn Lawlor, Ian Wicks, Ian Campell, Andrew Roberts, Donald Metcalf
-
Publication number: 20060069023Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in hormone signalling. The present invention further provides an animal model useful for screening for agents capable of agonizing or antagonizing hormone signalling. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in growth hormone signalling. The present invention further comprises a genetically modified animal. More particularly, the animals are genetically modified such that they have altered growth hormone signalling. The genetically modified animals of the present invention range from laboratory animals useful inter alia for animal models for studying hormone regulation and for the development of therapeutic protocols predicated, in part, on modulating hormone signalling to livestock animals.Type: ApplicationFiled: September 19, 2005Publication date: March 30, 2006Inventors: Warren Alexander, Donald Metcalf, Christopher Greenhalgh
-
Publication number: 20060003377Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: ApplicationFiled: August 29, 2005Publication date: January 5, 2006Applicant: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas Hilton, Warren Alexander, Elizabeth Viney, Tracy Willson, Rachael Richardson, Robyn Starr, Sandra Nicholson, Donald Metcalf, Nicos Nicola
-
Publication number: 20050208521Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: ApplicationFiled: November 17, 2004Publication date: September 22, 2005Inventors: Douglas Hilton, Warren Alexander, Elizabeth Viney, Tracy Willson, Rachael Richardson, Robyn Starr, Sandra Nicholson, Donald Metcalf, Nicos Nicola
-
Patent number: 6911530Abstract: The present invention relates generally to a novel haemopoietin receptor or components or part thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: October 13, 2000Date of Patent: June 28, 2005Assignee: Amrad Operations, Pty., Ltd.Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Patent number: 6905842Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: GrantFiled: October 31, 1997Date of Patent: June 14, 2005Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Patent number: 6870031Abstract: The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.Type: GrantFiled: December 7, 2001Date of Patent: March 22, 2005Assignee: Amrad Operations Pty. Ltd.Inventors: Douglas James Hilton, Tracy Willson, Timothy Gainsford, Warren S Alexander, Donald Metcalf, Ashley Ng, Nicos A Nicola
-
Publication number: 20050004015Abstract: The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.Type: ApplicationFiled: December 7, 2001Publication date: January 6, 2005Inventors: Douglas Hilton, Tracy Willson, Timothy Gainsford, Warren Alexander, Donald Metcalf, Ashley Ng, Nicos Nicola
-
Publication number: 20030004098Abstract: The present invention provides isolated DNA molecules encoding human and murine LIF and methods of producing LIF by the expression of the isolated DNA in suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.Type: ApplicationFiled: February 12, 2001Publication date: January 2, 2003Inventors: David Paul Gearing, Nicholas Martin Gough, Douglas James Hilton, Julie Ann King, Donald Metcalf, Edouard Collins Nice, Nicos Anthony Nicola, Richard John Simpson, Tracy Ann Willson
-
Publication number: 20020147307Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction.Type: ApplicationFiled: July 19, 2001Publication date: October 10, 2002Inventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Publication number: 20020090682Abstract: The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: November 7, 2001Publication date: July 11, 2002Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Patent number: 6414128Abstract: The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.Type: GrantFiled: September 17, 1998Date of Patent: July 2, 2002Assignee: Amrad Operations Pty. Ltd.Inventors: Douglas James Hilton, Tracy Willson, Timothy Gainsford, Warren S Alexander, Donald Metcalf, Ashley Ng, Nicos A Nicola
-
Patent number: 6387875Abstract: The present invention relates to a isolated leukaemia inhibitory factor (LIF)-binding protein (LBP) in soluble form and obtainable from a first mammalian species, said LBP capable of inhibiting the ability of LIF from a second mammalian species to induce differentiation of M1 myeloid leukaemic cells in vitro to a greater extent when compared to its ability to inhibit LIF from said first mammalian species.Type: GrantFiled: November 10, 1994Date of Patent: May 14, 2002Assignee: Amrad Corporation LimitedInventors: Nicos Anthony Nicola, Meredith Layton, Donald Metcalf, Richard J Simpson
-
Publication number: 20020045741Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: March 10, 1998Publication date: April 18, 2002Inventors: TRACY WILLSON, NICOS A. NICOLA, DOUGLAS J. HILTON, DONALD METCALF, JIAN GUO ZHANG